Dose homogeneity analysis of adjuvant radiation treatment in surgically resected brain metastases: Comparison of IORT, SRS, and IMRT indices.
Brain metastases
Gamma Knife
Homogeneity index
IMRT
IORT
Radiation
Journal
Brachytherapy
ISSN: 1873-1449
Titre abrégé: Brachytherapy
Pays: United States
ID NLM: 101137600
Informations de publication
Date de publication:
Historique:
received:
20
10
2020
revised:
10
11
2020
accepted:
10
11
2020
pubmed:
18
1
2021
medline:
20
8
2021
entrez:
17
1
2021
Statut:
ppublish
Résumé
Although surgery remains a treatment option for symptomatic brain metastases, the need for adjuvant radiation after surgery is widely accepted as standard. Despite a multitude of randomized trials aimed at identifying the ideal radiation treatment plan for surgically resected metastases, the development of new delivery regiments necessitates a periodic re-evaluation of dosimetric performance/outcome. Here, we compare the homogeneity index (HI) across three platforms: single-session stereotactic radiosurgery (SRS), multisession stereotactic radiotherapy, and intraoperative radiotherapy (IORT). Patients treated with IORT after surgical resection of brain metastases were identified and dosimetric parameters collected from the dose-volume histograms based on the development of conformal plans for adjuvant radiation using Gamma Knife-SRS (GK-SRS), linear accelerator based intensity-modulated radiation therapy, and IORT. HIs were calculated using four established methods and compared across platforms within the patient cohort. Statistical analyses were performed using analysis of variance. The mean maximal doses for the GK-SRS and IMRT plans were 30 Gy and 29 Gy with margin prescription doses of 16 Gy and 24 Gy, respectively. The IORT dose was 30 Gy to the applicator surface. HIs varied based on calculation methods, but maintained consistency when comparing across platforms with IORT having the lower mean HI value (0.56; 95% confidence interval (CI) 0.55-0.60) in single-fraction treatment, compared with GK-SRS (0.77; 95% CI 0.76-0.80). The mean multisession IMRT HI was lower than both single-fraction treatment modalities at 0.41 (95% CI 0.40-0.42). When using the HI as the primary dosimetric parameter for adjuvant radiation plans after surgical resection of brain metastases IORT offers improved dose homogeneity compared with GK-SRS in single-fraction treatment, whereas fractionated LINAC-based IMRT was superior with respect to the HI in comparison among all three methods.
Identifiants
pubmed: 33454200
pii: S1538-4721(20)30248-8
doi: 10.1016/j.brachy.2020.11.004
pmc: PMC7979458
mid: NIHMS1647231
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
426-432Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM121322
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Informations de copyright
Copyright © 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
Références
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):187-94
pubmed: 16814946
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8
pubmed: 10802351
J Appl Clin Med Phys. 2017 Jan;18(1):164-169
pubmed: 28291927
J Neurosurg. 2014 Dec;121 Suppl:69-74
pubmed: 25434939
J Neurooncol. 2015 May;123(1):103-11
pubmed: 25862006
J Neurooncol. 2019 Nov;145(2):391-397
pubmed: 31654248
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):333-42
pubmed: 16414369
J Neurosurg. 2016 Dec;125(Suppl 1):97-103
pubmed: 27903198
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1127-33
pubmed: 22981707
Lancet Oncol. 2017 Aug;18(8):1040-1048
pubmed: 28687375
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054
JAMA. 1998 Nov 4;280(17):1485-9
pubmed: 9809728
BMJ. 2020 Aug 19;370:m2836
pubmed: 32816842
J Neurooncol. 2005 Oct;75(1):5-14
pubmed: 16215811
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1142-8
pubmed: 27209508
J Neurosurg. 2019 Mar 22;132(4):1024-1032
pubmed: 30901747
Curr Oncol. 2019 Jun;26(3):e328-e333
pubmed: 31285676
Br J Radiol. 2012 Dec;85(1020):1546-50
pubmed: 22993386
Pract Radiat Oncol. 2020 Jan - Feb;10(1):36-43
pubmed: 31586666
Lancet. 2014 Feb 15;383(9917):603-13
pubmed: 24224997
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1231-9
pubmed: 8262852
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):436-442
pubmed: 29157748
J Neurosurg. 2006 Jun;104(6):907-12
pubmed: 16776334
J Clin Neurosci. 2018 Mar;49:48-55
pubmed: 29248376
Stereotact Funct Neurosurg. 2019;97(1):24-30
pubmed: 30763944
J Neurosurg. 2014 Dec;121 Suppl:75-83
pubmed: 25434940
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):618-630
pubmed: 30395902
J Neurooncol. 2018 Feb;136(3):545-553
pubmed: 29143275